Medindia LOGIN REGISTER
Medindia
Advertisement

Russia's Largest Breast Cancer Oncology Center Uses New CAD Software for Advanced Breast Cancer Detection

Monday, February 22, 2010 News on IT in Healthcare
Advertisement
- Parascript's AccuDetect technology used for earlier, more accurate identification of breast cancer at Russian Center for Roentgeno - Radiology Research -
Advertisement

BOULDER, Colo., Feb. 22 /PRNewswire/ -- Parascript, LLC, the image analysis and pattern recognition solution provider, today announced the use of its AccuDetect computer aided detection (CAD) software by the Russian Center for Roentgeno - Radiology Research (RNCRR) in Moscow. RNCRR is Russia's largest, most recognized breast cancer oncology center.
Advertisement

Breast cancer is the most common form of cancer in women in Russia and is the leading cause of cancer mortality. Only 60 percent of breast cancer is diagnosed at an early or localized stage.  Parascript AccuDetect is designed to contribute to better cancer detection and lower patient recalls through employment of complementary algorithms and two major, proprietary technology approaches.  The first approach detects the presence of suspicious lesions on mammogram images. The second utilizes sophisticated voting methods to combine the results from each algorithm to produce the highest sensitivity and lowest false-positive rates.

"As a premier medical institution specializing in early diagnostic and treatment of oncology diseases, RNCRR is dedicated to offering the most advanced technology to detect breast cancer earlier," said Dr. Nadezha I. Rozhkova, professor of oncology at RNCRR. "Parascript AccuDetect is an invaluable addition to our center that will benefit patients from all over Russia."  

More than 1,400 mammography acquisition stations are currently in use in Russia from manufacturers such as FujiFilm, General Electric, IMS and Siemens, among others. RNCRR utilizes modern mammography acquisition stations, including FujiFilm FCR Profect CS and GE Senographe Essential, in its Moscow facilities.  

"We look forward to continued adoption of our CAD solution in Russia and to a strong partnership with the renowned RNCRR," said Yuri Prizemin, director of product marketing for Parascript. "We are committed to applying our image analysis technology to help radiologists detect breast cancers earlier and with lower false-positive rates."

About RNCRR

RNCRR, founded in 1924, is a premier Russian medical institution specializing in early diagnosis and treatment of oncology diseases, including breast cancer. The Federal Mammography Center, operating under the auspices of Ministry of Health of the Russian Federation, is an integral part of RNCRR since 2000. The Center is conducting analysis of mammography equipment needs for all federal regions and is the primary institution to train radiologists in the diagnosis of breast mammary gland diseases. RNCRR employs highly qualified radiology experts and manages the largest database of patient cases in Russia. RNCRR is online at: http://www.rncrr.ru.

About Parascript, LLC

The Parascript image analysis suite extracts meaningful information from images. Employing patented digital image analysis and pattern recognition technologies, the Parascript image analysis suite improves decision quality in medical imaging, postal and payment automation, fraud detection, and forms processing operations. Parascript software processes over 100 billion imaged documents per year. Fortune 500 companies, postal operators, major healthcare, government, and financial institutions rely on Parascript products. Organizations include the U.S. Postal Service, Bowe Bell + Howell, CheckFree - now part of Fiserv, Elsag, Lockheed Martin, NCR, Siemens, and Unisys. Parascript is online at http://www.parascript.com.

SOURCE Parascript, LLC

Sponsored Post and Backlink Submission


Latest Press Release on News on IT in Healthcare

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close